Bone Biologics Corp Stock Fundamentals
| BBLG Stock | USD 1.22 0.04 3.17% |
Bone Biologics Corp fundamentals help investors to digest information that contributes to Bone Biologics' financial success or failures. It also enables traders to predict the movement of Bone Stock. The fundamental analysis module provides a way to measure Bone Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bone Biologics stock.
At this time, Bone Biologics' Depreciation And Amortization is most likely to increase significantly in the upcoming years. The Bone Biologics' current Research Development is estimated to increase to about 7.3 M, while EBIT is forecasted to increase to (8.5 M). Bone | Select Account or Indicator |
Bone Biologics Corp Company Shares Outstanding Analysis
Bone Biologics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Bone Biologics Shares Outstanding | 2.46 M |
Most of Bone Biologics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bone Biologics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bone Shares Outstanding Historical Pattern
Today, most investors in Bone Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bone Biologics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bone Biologics shares outstanding as a starting point in their analysis.
Bone Biologics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Bone Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Bone Biologics Corp has 2.46 M of shares currently outstending. This is 98.64% lower than that of the Health Care Equipment & Supplies sector and 98.59% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.57% higher than that of the company.
Bone Biologics Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bone Biologics's current stock value. Our valuation model uses many indicators to compare Bone Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bone Biologics competition to find correlations between indicators driving Bone Biologics's intrinsic value. More Info.Bone Biologics Corp is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Bone Biologics' Return On Equity is most likely to slightly decrease in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bone Biologics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Bone Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bone Biologics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bone Biologics could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics of similar companies.Bone Biologics is currently under evaluation in shares outstanding category among its peers.
Bone Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | (560.91 K) | ||||
| Shares Outstanding | 2.46 M | ||||
| Shares Owned By Insiders | 5.21 % | ||||
| Shares Owned By Institutions | 4.58 % | ||||
| Number Of Shares Shorted | 58.17 K | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.79 X | ||||
| EBITDA | 479.57 K | ||||
| Net Income | (8.95 M) | ||||
| Cash And Equivalents | 5.45 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 831.4 K | ||||
| Current Ratio | 80.11 X | ||||
| Book Value Per Share | 5.44 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Short Ratio | 0.18 X | ||||
| Earnings Per Share | (1.46) X | ||||
| Target Price | 16.75 | ||||
| Beta | 0.74 | ||||
| Market Capitalization | 3.1 M | ||||
| Total Asset | 3.74 M | ||||
| Retained Earnings | (80.91 M) | ||||
| Working Capital | 2.91 M | ||||
| Current Asset | 1.07 M | ||||
| Current Liabilities | 2.16 M | ||||
| Net Asset | 3.74 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 901.2 K | 602.3 K |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Bone Biologics Piotroski F Score and Bone Biologics Altman Z Score analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.